574 results on '"Cortot, Alexis"'
Search Results
2. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
3. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
4. Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study
5. Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
6. Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)
7. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review
8. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes
9. Unmet supportive care needs of caregivers according to medical settings of cancer patients: a cross-sectional study
10. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
11. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
12. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
13. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.
14. Troubles du système nerveux central sous lorlatinib : comment les détecter et les gérer en pratique ?
15. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
16. Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC
17. Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy
18. Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d’imagerie thoracique statement paper on lung cancer screening
19. When the MET receptor kicks in to resist targeted therapies
20. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study
21. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations
22. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
23. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer
24. Daily Caffeine Consumption May Increase the Risk of Acute Kidney Injury Related to Platinum-Salt Chemotherapy in Thoracic Cancer Patients: A Translational Study
25. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
26. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
27. Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology
28. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
29. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
30. Real-World Efficacy of the Dabrafenib-Trametinib (D-T) Combination in Braf V600e-Mutated Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Ifct-2004 Blade Cohort
31. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
32. MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation
33. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients
34. Current and Former Smokers: Who Wants To Be Screened?
35. MET amplification increases the metastatic spread of EGFR-mutated NSCLC
36. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
37. Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey
38. Defining the “Frequent Exacerbator” Phenotype in COPD: A Hypothesis-Free Approach
39. Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases
40. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis
41. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer
42. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
43. Dépistage du cancer en France : 10 ans d’analyse des comportements par les enquêtes EDIFICE
44. Efficacité des inhibiteurs du checkpoint immunitaire PD-1/PD-L1 et testing PD-L1 dans les cancers thoraciques
45. The multiple paths towards MET receptor addiction in cancer
46. Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site
47. MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice
48. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
49. Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer
50. Emotional distress, supportive care needs and age in the prediction of quality of life of cancer patients’ caregivers: A cross-sectional study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.